Compare AbbVie Inc (ABBV) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while iShares 10 20 Year Treasury Bond ETF trades at $98.37. The key difference: AbbVie Inc pays a 2.72% dividend while iShares 10 20 Year Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | TLH | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Fixed Income |
52-Week High | $261.07 | $105.36 |
52-Week Low | $184.85 | $97.13 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with strong technical momentum showing bullish moving average signals. The company demonstrates solid revenue growth, reaching $61.16B in 2025, though net margins have compressed to 5.79%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $2.65 exceeding the $2.59 forecast. Positive clinical trial results for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
AbbVie presents a favorable risk-reward profile with 68% analyst buy ratings and a $266.33 consensus price target offering 5.4% upside. Key opportunities include Skyrizi/Rinvoq growth offsetting Humira declines, while risks involve patent expirations in the 2030s and margin pressure. The stock's elevated P/E of 124.83 reflects growth expectations but warrants monitoring of execution against guidance.
TLH trades at $99.53, down 0.04% on the day, with technical indicators signaling a bearish trend. The stock shows no valuation or profitability metrics in the provided data, but upcoming dividends of $0.41 and $0.36 are scheduled for July 2026. Recent news highlights bond market volatility and Federal Reserve uncertainty, which may impact broader equity sentiment.
The outlook for TLH is cautious due to weak technical momentum and lack of fundamental data. Risks include macroeconomic pressures from potential rate hikes, while the dividend payments offer some income support. Investors should seek updated financials for a clearer assessment of the company's health and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
